AstraZeneca has revealed the results of phase IIIb study in adults with type 2 diabetes with inadequate glycemic control on metformin therapy.
The study revealed that treatment with onglyza 5mg and metformin was non-inferior compared to treatment with januvia 100mg and metformin, as measured by a change from baseline in HbA1c.
The company claims that the treatment with onglyza 5mg plus metformin had a safety profile similar to januvia 100mg plus metformin.
The company said that the study was designed to evaluate the efficacy and safety of onglyza (saxagliptin) 5mg and januvia 100mg in addition to metformin, in adults with type 2 diabetes who did not attain adequate glycemic control on metformin therapy alone.
According to the company, onglyza, a dipeptidyl peptidase 4 (DPP4) inhibitor, was recently approved by the European Commission as an adjunct to diet and exercise to improve blood sugar (glycemic) control in adults for the treatment of type 2 diabetes mellitus.
Andre Scheen, head of diabetes, nutrition and metabolic disorders and clinical pharmacology unit at Academic Hospital, said: “We are pleased with the findings from this study, which support that the addition of onglyza to metformin lowers HbA1c in adults with inadequate glycemic control despite treatment with metformin.”
AstraZeneca is involved in the research, development, manufacturing and marketing of prescription medicines and is a supplier for healthcare services.